Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

HUNGER

Showing results (941-950 of 1,174) with videos related to

Pageof 118
Sort By:
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology GroupKristina K Hardy, Leanne Embry, John A Kairalla, et al.
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.
Cancer Immunology Research|April 17, 2019
Siglec-9 Regulates an Effector Memory CD8<sup>+</sup> T-cell Subset That Congregates in the Melanoma Tumor MicroenvironmentQuentin Haas, Kayluz Frias Boligan, Camilla Jandus, et al.
Pediatric Blood & Cancer|March 2, 2011
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906W Paul Bowman, Eric L Larsen, Meenakshi Devidas, et al.
BMC Cancer|November 13, 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinomaRalf Gutzmer, Ulrike Leiter, Peter Mohr, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 11, 2018
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALLDominique R Perez, Christian K Nickl, Anna Waller, et al.
Pageof 118

Showing results (941-950 of 1,174) with videos related to

Sort By:
Pageof 118
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology GroupKristina K Hardy, Leanne Embry, John A Kairalla, et al.
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.
Cancer Immunology Research|April 17, 2019
Siglec-9 Regulates an Effector Memory CD8<sup>+</sup> T-cell Subset That Congregates in the Melanoma Tumor MicroenvironmentQuentin Haas, Kayluz Frias Boligan, Camilla Jandus, et al.
Pediatric Blood & Cancer|March 2, 2011
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906W Paul Bowman, Eric L Larsen, Meenakshi Devidas, et al.
BMC Cancer|November 13, 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinomaRalf Gutzmer, Ulrike Leiter, Peter Mohr, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 11, 2018
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALLDominique R Perez, Christian K Nickl, Anna Waller, et al.
Pageof 118